title: Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma.
abstract: OBJECTIVE
  The aim of this study is to compare tumoral microvessel density (MVD) and overall survival in two different groups of hepatocellular carcinoma (HCC), namely, viral hepatitis-related HCC (VHr-HCC) versus non-hepatitis-related HCC (NHr-HCC).
  
  
  METHODS
  Seventy-eight consecutive cases of HCC (47 hepatitis and 31 non-hepatitis cases) were studied. Microvessel numbers were assessed by staining for the antigens CD31, CD34, and CD240. The highest number of microvessel density and number of vessels were counted in the tumor, and the mean value represented the final MVD. Overall survival (OS) was analyzed between the two groups.
  
  
  RESULTS
  VHr-HCC and NHr-HCC were observed in 47 and 31 cases, respectively. No significant differences were seen between the VHr-HCC and NHr-HCC groups with respect to age, gender, or Child-Pugh class distribution. Mean number of vessels was significantly higher in Hr-HCC using CD31 (97.7 vs 83.7) and CD34 (82.4 vs 71.9) (p value 0.025 and 0.039, respectively). Higher MVD was detected in Hr-HCC compared to NHr-HCC using CD31 (4.9 vs 4.4) and CD34 (4.7 vs 4.3) (p value 0.0095 and 0.0190, respectively). No significant difference was observed between VHr-HCC and NHr-HCC using CD240 immunostaining for MVD (p value 0.0945 and 0.906, respectively). Overall survival was not statistically significantly different between VHr-HCC and NHr-HCC groups (p value 0.104).
  
  
  CONCLUSIONS
  HCC due to viral hepatitis has higher tumor microvessel formation and higher MVD values. This observation may explain the higher response of agents that target vascular endothelial growth factor (such as sorafenib) in patients with VHr-HCC.
authors: Department of Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA, AMOHAMED@MSM.EDU.
authors: Amr
authors: A
authors: Mohamed
authors: Avantika
authors: A
authors: Chenna
authors: Mohamed
authors: M
authors: Abdelfatah
authors: Jain
authors: J
authors: Sanjay
authors: M K
authors: MK
authors: Mohammad
authors: Ibrahim
authors: I
authors: Saber
authors: John
authors: J
authors: Kauh
authors: Balsam
authors: B
authors: Elhammali
authors: Ahmed
authors: A
authors: Kaseb
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000473:pathology / Q000821:virology*; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000302:isolation & purification; D006509:Hepatitis B / Q000473:pathology / Q000821:virology*; D006515:Hepatitis B virus / Q000302:isolation & purification; D006526:Hepatitis C / Q000473:pathology / Q000821:virology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000821:virology*; D008297:Male; D055806:Microvessels / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D018952:Antigens, CD34
references: J Gene Med. 2010 Dec;12(12):1002-13
references: 21157824
references: Clin Gastroenterol Hepatol. 2011 Nov;9(11):989-94
references: 21820396
references: Hepatology. 1998 Jun;27(6):1554-62
references: 9620326
references: J Clin Oncol. 2002 Apr 1;20(7):1775-85
references: 11919234
references: Aliment Pharmacol Ther. 2013 Jan;37(1):91-7
references: 23094860
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: J Clin Oncol. 2009 Mar 20;27(9):1485-91
references: 19224838
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: J Clin Gastroenterol. 2002 Sep;35(3):266-9
references: 12192205
references: J Gastroenterol. 2012 Sep;47(9):1030-5
references: 22402773
references: Carcinogenesis. 2000 Mar;21(3):505-15
references: 10688871
references: Int J Biol Markers. 2014 Sep 30;29(3):e279-87
references: 24803279
references: Lancet Oncol. 2009 Jan;10(1):25-34
references: 19095497
references: J Clin Pathol. 2004 Aug;57(8):867-71
references: 15280410
references: Science. 2002 Jun 28;296(5577):2404-7
references: 12089446
references: Biologics. 2008 Dec;2(4):779-88
references: 19707458
references: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references: 24399786
references: N Engl J Med. 1999 Mar 11;340(10):745-50
references: 10072408
references: Eur J Clin Invest. 2012 Dec;42(12):1309-16
references: 23078180
references: PLoS One. 2011 Feb 14;6(2):e16978
references: 21340026
references: Ann Surg. 2001 Feb;233(2):227-35
references: 11176129